Neonatal Fc Receptor Blocker [EPC]

4387 reported adverse events

Drugs of this class: EFGARTIGIMOD ALFA EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) ROZANOLIXIZUMAB

These side effects are most commonly reported by patients taking drugs of the Neonatal Fc Receptor Blocker [EPC] class:

# Side effect Count
0 MYASTHENIA GRAVIS 841
1 MYASTHENIA GRAVIS CRISIS 471
2 FATIGUE 453
3 DYSPNOEA 318
4 ASTHENIA 296
5 FALL 251
6 DRUG INEFFECTIVE 245
7 MUSCULAR WEAKNESS 232
8 URINARY TRACT INFECTION 231
9 HEADACHE 209
See all common reactions for Neonatal Fc Receptor Blocker [EPC]

Drugs of the Neonatal Fc Receptor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 THYMECTOMY 36 0.4091
1 MYASTHENIA GRAVIS CRISIS 471 0.3176
2 PROCEDURAL HEADACHE 74 0.1805
3 MYASTHENIA GRAVIS 841 0.1040
4 BULBAR PALSY 16 0.0578
5 THYMOMA 19 0.0526
6 SYMPTOM RECURRENCE 183 0.0306
7 CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY 39 0.0271
8 PLASMAPHERESIS 13 0.0249
9 MASTICATION DISORDER 40 0.0131
See all enriched reactions for Neonatal Fc Receptor Blocker [EPC]